5-bromo-1-(2-methoxyethyl)-3-nitropyridin-2(1H)-one | 784156-86-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 5-bromo-1-(2-methoxyethyl)-3-nitropyridin-2(1H)-one
• 英文别名: 5-bromo-1-(2-methoxyethyl)-3-nitropyridin-2-one
• CAS: 784156-86-1
• 化学式: C₈H₉BrN₂O₄
• 分子量: 277.074
• InChiKey: QZWDSYBNUPZRPB-UHFFFAOYSA-N

物化性质

• 沸点：
  324.0±42.0 °C(Predicted)
• 密度：
  1.68±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-bromo-1-(2-methoxyethyl)-3-nitropyridin-2(1H)-one 在 tin(ll) chloride 作用下， 以 乙酸乙酯 为溶剂， 生成 3-amino-5-bromo-1-(2-methoxyethyl)pyridin-2(1H)-one
  参考文献：
  名称：

  Calcitonin gene-related peptide (CGRP) receptor antagonists: Investigations of a pyridinone template

  摘要：

  In our effort to find potent, orally bioavailable CGRP receptor antagonists for the treatment of migraine, a novel series based on a pyridinone template was investigated. After optimizing the privileged structure and the placement of the attached phenyl ring, systematic SAR was carried out on both the N-alkyl and C-5 aryl substituents. Several analogs with good potency and pharmacokinetic profiles were identified. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.042
• 作为产物：
  描述：

  5-溴-2-羟基-3-硝基吡啶 、 2-溴乙基甲基醚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 生成 5-bromo-1-(2-methoxyethyl)-3-nitropyridin-2(1H)-one
  参考文献：
  名称：

  [EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS
  [FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES UTILISÉS EN TANT QU'INHIBITEURS DE JAK2

  摘要：

  本公开提供6-杂环氧基苯并咪唑和氮杂苯并咪唑化合物及其组合物，用于抑制JAK2。

  公开号：

  WO2022140527A1

文献信息

• [EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS<br/>[FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES EN TANT QU'INHIBITEURS DE JAK2
  申请人：AJAX THERAPEUTICS INC

  公开号：WO2021226261A1

  公开（公告）日：2021-11-11

  The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

  本公开提供了6-杂芳氧基苯并咪唑和氮杂苯并咪唑化合物及其组合物，用于抑制JAK2。
• CGRP receptor antagonists
  申请人：Burgey S. Christopher

  公开号：US20050256098A1

  公开（公告）日：2005-11-17

  The present invention is directed to compounds of Formula I: and Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I和式II的化合物：（其中变量R1、R2、R3、R4、A、B、G、J、Q、T、U、V、W、X和Y如此定义），这些化合物可用作CGRP受体的拮抗剂，并可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗参与CGRP的这些疾病。
• Cgrp Receptor Antagonists
  申请人：Paone V. Daniel

  公开号：US20080090806A1

  公开（公告）日：2008-04-17

  The present invention is directed to compounds of Formula (I) and Formula (II) (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式（I）和式（II）化合物（其中变量R1、R2、R3、R4、A、B、G、J、Q、T、U、V、W、X和Y的定义如本文所述），其作为CGRP受体拮抗剂在治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群性头痛中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的使用。
• CGRP RECEPTOR ANTAGONISTS
  申请人：Paone Daniel Vincent

  公开号：US20100298303A1

  公开（公告）日：2010-11-25

  The present invention is directed to compounds of Formula I: and Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I和式II的化合物：（其中变量R1，R2，R3，R4，A，B，G，J，Q，T，U，V，W，X和Y如本文所定义），其作为CGRP受体拮抗剂在治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛中具有用途。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• [EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS<br/>[FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES UTILISÉS EN TANT QU'INHIBITEURS DE JAK2
  申请人：AJAX THERAPEUTICS INC

  公开号：WO2022140527A1

  公开（公告）日：2022-06-30

  The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

  本公开提供6-杂环氧基苯并咪唑和氮杂苯并咪唑化合物及其组合物，用于抑制JAK2。